[go: up one dir, main page]

MX2018000239A - Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos. - Google Patents

Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos.

Info

Publication number
MX2018000239A
MX2018000239A MX2018000239A MX2018000239A MX2018000239A MX 2018000239 A MX2018000239 A MX 2018000239A MX 2018000239 A MX2018000239 A MX 2018000239A MX 2018000239 A MX2018000239 A MX 2018000239A MX 2018000239 A MX2018000239 A MX 2018000239A
Authority
MX
Mexico
Prior art keywords
formula
agents
bifosphonates
teranostic
hbed
Prior art date
Application number
MX2018000239A
Other languages
English (en)
Other versions
MX377208B (es
Inventor
F Kung Hank
Rye Choi Seok
Wu Zehui
Ploessl Karl
Zha Zhihao
Original Assignee
Five Eleven Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Five Eleven Pharma Inc filed Critical Five Eleven Pharma Inc
Publication of MX2018000239A publication Critical patent/MX2018000239A/es
Publication of MX377208B publication Critical patent/MX377208B/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3839Polyphosphonic acids
    • C07F9/3873Polyphosphonic acids containing nitrogen substituent, e.g. N.....H or N-hydrocarbon group which can be substituted by halogen or nitro(so), N.....O, N.....S, N.....C(=X)- (X =O, S), N.....N, N...C(=X)...N (X =O, S)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0489Phosphates or phosphonates, e.g. bone-seeking phosphonates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/0497Organic compounds conjugates with a carrier being an organic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/003Compounds containing elements of Groups 3 or 13 of the Periodic Table without C-Metal linkages
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/28Phosphorus compounds with one or more P—C bonds
    • C07F9/38Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)]
    • C07F9/3804Phosphonic acids [RP(=O)(OH)2]; Thiophosphonic acids ; [RP(=X1)(X2H)2(X1, X2 are each independently O, S or Se)] not used, see subgroups
    • C07F9/3808Acyclic saturated acids which can have further substituents on alkyl
    • C07F9/3817Acids containing the structure (RX)2P(=X)-alk-N...P (X = O, S, Se)
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6515Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having three nitrogen atoms as the only ring hetero atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6524Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having four or more nitrogen atoms as the only ring hetero atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Optics & Photonics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Radiology & Medical Imaging (AREA)

Abstract

La presente invención se refiere a compuestos de acuerdo con la formula I o formula II que son agentes de toma de imágenes óseas potenciales; ciertos compuestos etiquetados con 68Ga mostraron excelente captación y retención ósea; la presente invención también se refiere a composiciones farmacéuticas que comprenden un portador farmacéuticamente aceptable y un compuesto de formula I o formula II o una sal farmacéuticamente aceptable del mismo.(ver formula I y formula II).
MX2018000239A 2015-07-07 2016-07-06 Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos. MX377208B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562189652P 2015-07-07 2015-07-07
US201662320296P 2016-04-08 2016-04-08
PCT/US2016/041040 WO2017007790A1 (en) 2015-07-07 2016-07-06 Hbed-bisphosphonates, radiometal conjugates thereof and their use as theranostic agents

Publications (2)

Publication Number Publication Date
MX2018000239A true MX2018000239A (es) 2018-05-23
MX377208B MX377208B (es) 2025-03-07

Family

ID=57685907

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018000239A MX377208B (es) 2015-07-07 2016-07-06 Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos.

Country Status (12)

Country Link
US (1) US10253052B2 (es)
EP (1) EP3319643B1 (es)
JP (1) JP6792875B2 (es)
KR (1) KR102651945B1 (es)
CN (1) CN107847618B (es)
AU (1) AU2016289474C1 (es)
CA (1) CA2991498A1 (es)
DK (1) DK3319643T3 (es)
EA (1) EA201890221A1 (es)
IL (1) IL256726A (es)
MX (1) MX377208B (es)
WO (1) WO2017007790A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX377208B (es) 2015-07-07 2025-03-07 Five Eleven Pharma Inc Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos.
TW201832750A (zh) * 2017-03-02 2018-09-16 美商511製藥公司 放射性藥品標記裝置
US11723992B2 (en) * 2018-08-03 2023-08-15 Board Of Regents, The University Of Texas System Method for extraction and purification of 68GA
CN109438517B (zh) * 2018-12-27 2021-01-08 北京久杰净化工程技术有限公司 一种与羰基金属核心配位的双功能连接剂的配合物及其制备方法
KR20220004125A (ko) * 2019-04-26 2022-01-11 파이브 일레븐 파마 인크. 진단제 및 방사성핵종 치료제로서의 전립선-특이적 막 항원 (psma) 억제제
US20230001027A1 (en) * 2019-10-01 2023-01-05 City Of Hope Metal chelating agents and methods of using the same
DE102022105175A1 (de) * 2022-03-04 2023-09-07 Atoms for Cure GmbH Markierungsvorläufer und Radiotracer mit drei oder mehr Targeting-Vektoren für die nuklearmedizinische Theranostik

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE329623T1 (de) * 2001-10-22 2006-07-15 Dow Global Technologies Inc Radiopharmazeutishes mittel zur behandlung von krebs im frühstadium
JP2006523237A (ja) * 2003-04-03 2006-10-12 セマフォア ファーマシューティカルズ, インコーポレイテッド Pi−3キナーゼインヒビタープロドラッグ
US7161000B2 (en) * 2003-05-30 2007-01-09 Sumitomo Chemical Company, Limited Method for producing phenol condensate
US10925977B2 (en) * 2006-10-05 2021-02-23 Ceil>Point, LLC Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
CN104774175B (zh) * 2007-06-26 2019-04-16 约翰·霍普金斯大学 标记的前列腺特异性膜抗原(psma)的抑制子、生物学评估及作为成像试剂的用途
US20120148492A1 (en) * 2009-08-20 2012-06-14 Fujifilm Ri Pharma Co., Ltd. Bisphosphonic acid derivative and compound thereof labeled with radioactive metal nuclide
EP2697347B1 (en) * 2011-04-13 2016-11-16 Firmenich SA Equilibrated dynamic mixtures to control the release of perfuming aldehydes and ketones
ITMI20121156A1 (it) 2012-06-29 2013-12-30 Consiglio Nazionale Ricerche Metodo di elaborazione di immagini di tomografia a coerenza ottica
EP2862857A1 (en) * 2013-10-18 2015-04-22 Deutsches Krebsforschungszentrum Labeled inhibitors of prostate specific membrane antigen (PSMA), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
MX377208B (es) 2015-07-07 2025-03-07 Five Eleven Pharma Inc Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos.

Also Published As

Publication number Publication date
US10253052B2 (en) 2019-04-09
AU2016289474B2 (en) 2020-12-24
AU2016289474C1 (en) 2021-04-08
CN107847618A (zh) 2018-03-27
AU2016289474A1 (en) 2018-02-01
JP2018524352A (ja) 2018-08-30
IL256726A (en) 2018-03-29
KR20180026736A (ko) 2018-03-13
WO2017007790A1 (en) 2017-01-12
HK1254864A1 (en) 2019-07-26
EP3319643A1 (en) 2018-05-16
CA2991498A1 (en) 2017-01-12
DK3319643T3 (da) 2020-06-15
EP3319643B1 (en) 2020-04-22
CN107847618B (zh) 2021-07-16
JP6792875B2 (ja) 2020-12-02
MX377208B (es) 2025-03-07
US20170022224A1 (en) 2017-01-26
KR102651945B1 (ko) 2024-03-26
WO2017007790A9 (en) 2018-01-04
EA201890221A1 (ru) 2018-06-29
EP3319643A4 (en) 2019-04-10

Similar Documents

Publication Publication Date Title
MX2018000239A (es) Bifosfonatos de hbed, sus conjugados radio metalicos y su uso como agentes teranosticos.
CL2023001909A1 (es) Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo
ZA201906832B (en) Novel psma-binding agents and uses thereof
MX375570B (es) Conjugados de pirrolobenzodiazepina
EA201692002A1 (ru) Стабильные составы для антител к cd19 и конъюгатов антитело-лекарственное средство
EA201891083A1 (ru) Составы антител к cd38 для подкожного введения и их применение
MA39362A1 (fr) Compositions stables d'iode non complexé et procédés d'utilisation.
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
EA201691988A1 (ru) Производные бороновой кислоты и их терапевтическое применение
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
CL2016003422A1 (es) Inhibidores de demetilasa-1 específico de lisina
CY1124425T1 (el) Συνθεσεις οι οποιες περιλαμβανουν συζευγματα φαρμακου αντισωματος-δουοκαρμυκινης
EA201591728A1 (ru) Гетероциклические соединения и способы их применения
CL2016003423A1 (es) Inhibidores de demetilasa-1 específico de lisina
MX2017005199A (es) Conjugados y reactivos de conjugacion.
MX376122B (es) Composiciones de plinabulina.
EA201890898A1 (ru) Новые соединения и конъюгаты криптофицина, их получение и их терапевтическое применение
CL2017002856A1 (es) Compuestos de tioéter como inhibidores de la nitrificación
CU20170012A7 (es) Anticuerpos anti proteína similar a angiopoyetina 4
SV2019005838A (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
MX394833B (es) Formulaciones con mejora de la estabilidad.
EA201591717A1 (ru) Твердые формы гидрохлорида вемурафениба
AU2016356504A8 (en) 5-hydroxytryptamine 1B receptor-stimulating agent for enhancing in vivo engraftment potential
MX2016003725A (es) Compuestos y su uso para la preparacion de agentes de formacion de imagen tau y formulaciones para la formacion de imagen tau.
MX386402B (es) Tratamiento con trastuzumab vc-seco-duba de pacientes de cáncer refractarios a trastuzumab emtansina.

Legal Events

Date Code Title Description
FG Grant or registration